Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

(TM), a late-stage vaccine candidate for the treatment of advanced prostate cancer, was acquired as part of the partnership that was entered with the National Cancer Institute. Very promising data were reported, showing prolonged survival combined with a favourable safety profile. Phase III studies expected to be initiated in 2010. - MVA-BN(R) Anthrax, a new preclinical programme for an anthrax vaccine, is expected to enter clinical trials in 2010. - MVA-BN(R) HIV multiantigen, in development as prophylactic and therapeutic vaccine against HIV, initiated clinical Phase I/II trials. - The company's MVA-BN(R) based prostate cancer vaccine also entered clinical Phase I/II trials. - A milestone payment of USD 25 million was received after submission of important IMVAMUNE(R) data. - The data that were generated from a larger Phase II study with IMVAMUNE(R) was submitted to the US health authorities for evaluation whether they can potentially support the use of IMVAMUNE(R) in a declared emergency. - More than 2,400 subjects have now been vaccinated with IMVAMUNE(R) - The first IMVAMUNE(R) contracts outside USA were signed with Canada and an Asian country.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "2008 was a successful year for Bavarian Nordic where all our primary goals were achieved. We implemented a new strategy, and this has already borne fruit. Our increased focus on cancer therapies which through to the partnership with the NCI led to the acquisition of PROSTVAC(TM) has strengthened our pipeline and we feel very optimistic about our cancer vaccines in the future. At the end of the year, we submitted the important safety data for IMVAMUNE(R) to the US health authorities and are now awaiting just one approval in order to initiate the delivery of the 20 million doses under the RFP-3
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),abiophar...zingnovelpainmanagementtherapies,announcedtodaytha...isscheduledtopresentatthe21stAnnualPiperJaffrayHea...YorkPalaceHotelinNewYork,NewYork. ,, Mr.DiTonno...ailabletorespondtoquestionsduringthepresentationsa...
(Date:11/24/2009)...rbleEnergyCorp.announcedtodaythatthecompanyandtheO...warded$2millionbyWashingtonState,sCommunityEconomi...shiptoconstructthestate,sfirstspecialtybiochemical...ntwillsignificantlyspeedthedevelopmentofourbiorefi...ueMarbleEnergyCEOKellyOgilvie."WearegratefultotheG...
(Date:11/24/2009)...orpatientswithadvanced-stage,orrecurrentendometria...Call/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ)(t...donendocrinetherapyandoncology,todayannouncedposit...toxicpeptideconjugate,AEZS-108(formerlyAN-152),inp...apersonalizedhealthcareapproach,thestudyselectedpa...
(Date:11/24/2009)...Call/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglobal...hatithassubmittedaMAAtotheEuropeanMedicinesAgencyf...therapyindevelopment,forthetreatmentofType1Gaucher...glucerasealfathathasbeensubmitted,withprevious,sub...aglobalsupplyshortageofthecurrentlyapprovedandmark...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...stry publication R&D Directions honors Dr. Sel...dies , , CINCINNATI, March 26 Kendle (Nasdaq: ...search organization, today announced Edward Seller...f the company,s Early Stage Unit in Toronto, has b...by leading industry publication R&D Direction...
...DIEGO, March 26 David Koos, Chairman and CEO of S...OTC Bulletin Board: BMSN) announced today that the...25 by researchers at the National Institutes of He...for Leukemia treatment and artificially culturing ...ll "storage" facilities that meet rigid state and ...
... , SAN JOSE, Calif., March 26 NeuroSky, Inc., a b...nnounces today the launching of the MindSet(TM), a...ional technology for a wireless Bluetooth(R) heads...products. With two earlier toy companies announcin...TM) and the Uncle Milton Force Trainer(TM) (und...
Other Biology Technology:Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 2Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 3NIH News Confirms Trend in Stem Cell 'Storage' Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group 2NeuroSky to Launch Brainwave-Based Technology for Stereo Headsets for Personal Computers 2NeuroSky to Launch Brainwave-Based Technology for Stereo Headsets for Personal Computers 3
(Date:11/25/2009)...eat may be just as vital to your health as what yo... Biological Studies. Their experiments in mice rev...s of genes in the liverthe body,s metabolic cleari... by the body,s circadian clock as conventional wis...ctivity of a large number of genes completely inde...
(Date:11/24/2009)...ng new doors to understanding how sounds associate...rine mammal or if they hear it at all. , The sa...hat NASA uses to detect flaws in the space shuttle...entists to peek inside the giant head of a whale. ... replicas of a whale,s hearing anatomy using a bre...
(Date:11/24/2009)... of a remarkable class of ring-shaped protein moto...ence Berkeley National Laboratory (Berkeley Lab) u...amline at the Advanced Light Source (ALS). These p...n and replication, and are vital to the survival o...ts, such as the human papillomavirus, which has be...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3Rocket science leads to new whale discovery 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Prometheus Launches ProOnc Dx Cancer Diagnostics 5507 1Prometheus Launches ProOnc Dx Cancer Diagnostics 5507 2Prometheus Launches ProOnc Dx Cancer Diagnostics 5507 3Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax 28R 29 Sprinkle Capsules 5505 1Aethlon Medical Announces Presentation of Hepatitis C 28HCV 29 Clinical Data at 42nd Annual American Society of Nephrology 28ASN 29 Conference 5503 1Aethlon Medical Announces Presentation of Hepatitis C 28HCV 29 Clinical Data at 42nd Annual American Society of Nephrology 28ASN 29 Conference 5503 2Aethlon Medical Announces Presentation of Hepatitis C 28HCV 29 Clinical Data at 42nd Annual American Society of Nephrology 28ASN 29 Conference 5503 3
...ovember 13, 2008) In a report now available onlin...ber 2008 issue of the Journal of Urology, Univer...Herr, PhD and his colleagues have confirmed the ac...e first FDA approved at-home immunodiagnostic test...rr, a professor of Cell Biology and director of UV...
...8) -- Not knowing which way is up can have deadly ...ses, called spatial disorientation, is responsible...s in the United States, with 90 percent of these b...nistration. , Although there have been no spatia... concern for astronaut pilots. A National Space Bi...
...s" are so sensitive that they can feel the tell-ta...d samples, yet don,t ever need to be sterilizedor ... National Institute of Standards and Technology (N...chnique for detecting and measuring very small con...us on a surface. NIST has issued a non-exclusive l...
Other Biology News:First at-home test for vasectomized men proves to be safe, accurate 2Space researchers developing tool to help disoriented pilots 2Space researchers developing tool to help disoriented pilots 3
XTT (23-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) from Molecular Probes (Invitrogen)
... background information, detailed practical inform...ins including: the HIV growth cycle; reverse trans...Expression of HIV proteins using baculoviruses; RN...ractions; transient assays for Nef-induced down re...
Sheep Anti-Mouse TREM-2 Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Ferret Whole Serum Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Biology Products: